https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2024-11-14 18:16:202024-11-14 18:17:05ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2024-10-21 10:19:472024-10-21 10:22:593B Pharmaceuticals Announces Option and Asset Purchase Agreement with Novartis for PSMA Radioligand Therapy Program
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2023-09-20 11:45:522023-09-21 11:46:21RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2023-04-24 11:43:472023-04-24 11:46:523B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00Jan Michelhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngJan Michel2022-12-22 17:20:342022-12-22 17:21:513BP company statement re recent events involving Clovis Oncology and FAP-2286
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2022-06-10 10:35:482022-06-13 10:39:593B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6th Theranostic World Congress
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2020-03-25 11:10:502020-05-12 16:40:50Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2019-09-23 12:31:552019-10-11 15:44:33Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2018-11-20 12:03:042019-09-27 14:21:33Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2017-03-22 11:58:412019-09-27 14:21:543B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2016-11-08 14:44:312019-07-26 16:12:50KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2016-02-17 17:02:412019-07-26 12:28:00Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology
